Language disturbances in schizophrenia: the relation with antipsychotic medication

被引:48
|
作者
de Boer, J. N. [1 ,2 ,3 ,4 ]
Voppel, A. E. [3 ,4 ]
Brederoo, S. G. [3 ,4 ]
Wijnen, F. N. K. [5 ]
Sommer, I. E. C. [3 ,4 ]
机构
[1] Univ Utrecht, Univ Med Ctr Utrecht, Dept Psychiat, Utrecht, Netherlands
[2] Brain Ctr Rudolf Magnus, Utrecht, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands
[4] Dept Psychiat, Groningen, Netherlands
[5] Univ Utrecht, Utrecht Inst Linguist OTS, Utrecht, Netherlands
来源
NPJ SCHIZOPHRENIA | 2020年 / 6卷 / 01期
关键词
PARKINSONS-DISEASE; THOUGHT-DISORDER; SPEECH RATE; 2ND-GENERATION ANTIPSYCHOTICS; HIGH-RISK; DOPAMINE; RECEPTORS; COMMUNICATION; COGNITION; ABNORMALITIES;
D O I
10.1038/s41537-020-00114-3
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Language disturbances are key aberrations in schizophrenia. Little is known about the influence of antipsychotic medication on these symptoms. Using computational language methods, this study evaluated the impact of high versus low dopamine D(2)receptor (D2R) occupancy antipsychotics on language disturbances in 41 patients with schizophrenia, relative to 40 healthy controls. Patients with high versus low D2R occupancy antipsychotics differed by total number of words and type-token ratio, suggesting medication effects. Both patient groups differed from the healthy controls on percentage of time speaking and clauses per utterance, suggesting illness effects. Overall, more severe negative language disturbances (i.e. slower articulation rate, increased pausing, and shorter utterances) were seen in the patients that used high D2R occupancy antipsychotics, while less prominent disturbances were seen in low D2R occupancy patients. Language analyses successfully predicted drug type (sensitivity = 80.0%, specificity = 76.5%). Several language disturbances were more related to drug type and dose, than to other psychotic symptoms, suggesting that language disturbances may be aggravated by high D2R antipsychotics. This negative impact of high D2R occupancy drugs may have clinical implications, as impaired language production predicts functional outcome and degrades the quality of life.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Antipsychotic medication for childhood-onset schizophrenia
    Kennedy, E.
    Kumar, A.
    Datta, S. S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [32] THE RESULTS OF NONADHERENCE TO ANTIPSYCHOTIC MEDICATION IN PATIENTS WITH SCHIZOPHRENIA
    Dogan, Orhan
    ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, 2013, 14 (01):
  • [33] Sexual dysfunction in patients with schizophrenia on antipsychotic medication
    Uecok, Alp
    Incesu, Cem
    Aker, Tamer
    Erkoc, Sahap
    EUROPEAN PSYCHIATRY, 2007, 22 (05) : 328 - 333
  • [34] Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
    Joe, Soohyun
    Ahn, Joonho
    Choi, Youngmin
    Lee, JungSun
    Park, Jangho
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 192 - 193
  • [35] Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation to Symptom Severity, Cognition and Antipsychotic Medication
    Veijola, Juha
    Guo, Joyce Y.
    Moilanen, Jani S.
    Jaaskelainen, Erika
    Miettunen, Jouko
    Kyllonen, Merja
    Haapea, Marianne
    Huhtaniska, Sanna
    Alaraisanen, Antti
    Maki, Pirjo
    Kiviniemi, Vesa
    Nikkinen, Juha
    Starck, Tuomo
    Remes, Jukka J.
    Tanskanen, Paivikki
    Tervonen, Osmo
    Wink, Alle-Meije
    Kehagia, Angie
    Suckling, John
    Kobayashi, Hiroyuki
    Barnett, Jennifer H.
    Barnes, Anna
    Koponen, Hannu J.
    Jones, Peter B.
    Isohanni, Matti
    Murray, Graham K.
    PLOS ONE, 2014, 9 (07):
  • [36] Subjective Cognitive Complaints in Schizophrenia: Relation to Antipsychotic Medication Dose, Actual Cognitive Performance, Insight and Symptoms
    Sellwood, William
    Morrison, Anthony P.
    Beck, Rosie
    Heffernan, Suzanne
    Law, Heather
    Bentall, Richard P.
    PLOS ONE, 2013, 8 (12):
  • [37] Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
    Haddad, Peter M.
    Brain, Cecilia
    Scott, Jan
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 43 - 62
  • [38] Continuity of Antipsychotic Medication Management for Medicaid Patients With Schizophrenia
    Farley, Joel F.
    Wang, Chi-Chuan
    Hansen, Richard A.
    Voils, Corrine I.
    Maciejewski, Matthew L.
    PSYCHIATRIC SERVICES, 2011, 62 (07) : 747 - 752
  • [39] Neuroinflammation in schizophrenia and effects of antipsychotic medication - a PET study
    Holmes, S. E.
    Hinz, R.
    Green, M.
    Anton-Rodriguez, J.
    Gerhard, A.
    Drake, R.
    Talbot, P. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S135 - S135